The GAO has released a report entitled “Brand-Name Prescription Drug Pricing: Lack of Therapeutically Equivalent Drugs and Limited Competition May Contribute to Extraordinary Price Increases.” According to the GAO, during the period of 2000 to 2008, 416 brand-name drug products had “extraordinary” price increases, defined as a price increase of 100% or more at a single point in time. More than half of the brand-name drug products that had extraordinary price increases were in three therapeutic classes—central nervous system, anti-infective, and cardiovascular. The GAO reports that a lack of therapeutically-equivalent drugs (both generics and other brand-name drugs used to treat the same condition) and limited competition may contribute to extraordinary price increases.